<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.86099</article-id><article-id pub-id-type="publisher-id">ACM-26582</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180600000_88570093.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  以粪便为基础的大肠癌筛查
  The Screening for Colorectal Cancer on the Basis of Feces
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>葵花</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>湖北科技学院临床医学院，湖北 咸宁</addr-line></aff> <pub-date pub-type="epub"><day>31</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>06</issue><fpage>590</fpage><lpage>595</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    大肠癌是我国常见的消化道恶性肿瘤之一，早期筛查具有十分重要的意义。由于粪便检查成本低、且病人无痛苦、无损伤性，易为病人接受。本文以粪便为基础的大肠癌筛查作一综述，为今后大肠癌的筛查工作提供帮助。
    Colorectal cancer is one of the most common gastrointestinal cancers. Early screening is of great significance. Because the stool examination is low in cost and the patient is painless and nonde-structive, it is easy for patients to accept. In this paper, the screening for colorectal cancer on the basis of feces is reviewed, which will help for developing CRC screening in the future. 
  
 
</p></abstract><kwd-group><kwd>大肠癌，筛查，粪便检查, Colorectal Cancer</kwd><kwd> Screening</kwd><kwd> Stool Examination</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>以粪便为基础的大肠癌筛查<sup> </sup></title><p>卢葵花</p><p>湖北科技学院临床医学院，湖北 咸宁</p><p><img src="//html.hanspub.org/file/16-1570631x1_hanspub.png" /></p><p>收稿日期：2018年7月29日；录用日期：2018年8月20日；发布日期：2018年8月27日</p><disp-formula id="hanspub.26582-formula40"><graphic xlink:href="//html.hanspub.org/file/16-1570631x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>大肠癌是我国常见的消化道恶性肿瘤之一，早期筛查具有十分重要的意义。由于粪便检查成本低、且病人无痛苦、无损伤性，易为病人接受。本文以粪便为基础的大肠癌筛查作一综述，为今后大肠癌的筛查工作提供帮助。</p><p>关键词 :大肠癌，筛查，粪便检查</p><disp-formula id="hanspub.26582-formula41"><graphic xlink:href="//html.hanspub.org/file/16-1570631x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by author and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/16-1570631x7_hanspub.png" /> <img src="//html.hanspub.org/file/16-1570631x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>大肠癌(colorectal cancer, CRC)是我国常见的消化道恶性肿瘤。随着人们生活方式以及饮食结构的改变，我国大肠癌的发病率在逐年升高，已跃居第3~5位 [<xref ref-type="bibr" rid="hanspub.26582-ref1">1</xref>] 。大肠癌的预后与早期诊断密切关系，大肠癌的早期筛查具有十分重要的意义。</p><p>大肠癌的筛查有以粪便为基础的筛查、以血清为基础的筛查以及结肠镜筛查等。由于粪便检查成本低、且病人无痛苦、无损伤性，易为病人接受。本文以粪便为基础的大肠癌筛查作一综述。</p></sec><sec id="s4"><title>2. 粪便隐血试验(Faecal Occult Blood Testing, FOBT)</title><p>粪便隐血试验是一种简单、经济、无痛苦的筛查大肠癌方法，是大肠癌初筛最常用的方法。其检查方法主要包括化学法、免疫法和转铁蛋白法。</p><sec id="s4_1"><title>2.1. 化学法粪便隐血试验(Guaiac Fecal Occult Blood Tests, gFOBT)</title><p>化学法有愈创木酯化学法、联苯胺化学法、邻联甲苯胺法、匹拉米洞化学法等，最常用的是愈创木酯化学法。该方法是1864年由Vandeen发明，1901年Boas将该方法用于大肠癌的筛查。Li等 [<xref ref-type="bibr" rid="hanspub.26582-ref2">2</xref>] 研究表明，愈创木酯法在大肠癌的筛查中效能较高，具有价格便宜、检测方法便捷等优势。欧洲及美国大型的随机试验显示化学法可以减少大肠癌的死亡率 [<xref ref-type="bibr" rid="hanspub.26582-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.26582-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.26582-ref5">5</xref>] 。在欧洲的筛查试验中，每两年行一次化学法粪便隐血试验可以降低13%~18%大肠癌相关的死亡率 [<xref ref-type="bibr" rid="hanspub.26582-ref4">4</xref>] 。但gFOBT结果易受饮食等诸多因素的影响，敏感性和特异性较差 [<xref ref-type="bibr" rid="hanspub.26582-ref5">5</xref>] 。服用某些食物如动物血、肉、肝脏、铁剂、富含叶绿素的蔬菜等会出现假阳性，服用维生素C和一些具有还原作用的药物等会出现假阴性。因此，gFOBT已不是大肠癌筛查的首选试验。</p></sec><sec id="s4_2"><title>2.2. 免疫法粪便隐血试验(Immuno Fecal Occult Blood Tests, iFOBT)</title><p>免疫法常用的有免疫胶体金法，如酶联免疫吸附试验(ELISA)、免疫单项扩散法、对流免疫电泳法等。免疫法基本不受动物血血红蛋白、铁剂、药物、过含氧化物酶蔬菜等的影响。Lane等 [<xref ref-type="bibr" rid="hanspub.26582-ref6">6</xref>] 的研究结果显示， iFOBT检出大肠癌的敏感性86%，检出腺瘤样息肉的敏感性64%。Faivre等 [<xref ref-type="bibr" rid="hanspub.26582-ref7">7</xref>] 研究显示，iFOBT比gFOBT能够更准确检出腺瘤样息肉和大肠癌，iFOBT法大肠癌检出率比gFOBT法高 1.5~2.5 倍，腺瘤样息肉检出率高2~4倍。Morikawa等 [<xref ref-type="bibr" rid="hanspub.26582-ref8">8</xref>] 研究显示，免疫法对大肠癌的敏感性是65.8%，对大于或等于1 cm腺瘤或高级别上皮内瘤变的敏感性是27.1%，且免疫法发现左半结肠腺瘤比右半结肠腺瘤的敏感性明显增高。Allison等 [<xref ref-type="bibr" rid="hanspub.26582-ref9">9</xref>] 开展的前瞻性随机对照研究显示，免疫法发现大肠癌的敏感性为81.8%，特异性为96.9%；化学法的敏感性为64.3%，特异性为和90.1%；对于大于或等于1 cm腺瘤，免疫法的敏感性为29.5%，特异性为96.9%；化学法的敏感性为40.3%，特异性为90.6%。</p><p>iFOBT是目前最主要的非侵袭性检查，其高敏感、特异性明显优于其他基于粪检的大肠癌筛查方法。其缺点是：对于不伴有出血的肿瘤人群，iFOBT检查结果会出现假阴性；对于iFOBT为阳性者，确诊还需要做进一步的检查。因此，iFOBT目前只适合作为大肠癌的初期筛查。</p></sec><sec id="s4_3"><title>2.3. 转铁蛋白法粪便隐血试验(Transferrin Fecal Occult Blood Test, tFOBT)</title><p>转铁蛋白法是近期研究较多的粪便隐血试验检测方法。转铁蛋白(transferrin)主要存在于血浆中，主要在肝脏合成。在有消化道出血的疾病中，转铁蛋白与血红蛋白相似，也会漏入肠道并随粪便排入体外。健康人的粪便中几乎不存在转铁蛋白，而有胃肠道出血的粪便，存在大量转铁蛋白。粪便中的转铁蛋白抵抗消化酶及细菌的作用较强，在粪便中稳定性较血红蛋白高，因此在方法学上，转铁蛋白法与免疫法有较好的互补。Miyoshi等 [<xref ref-type="bibr" rid="hanspub.26582-ref10">10</xref>] 研究发现，联合血红蛋白法和转铁蛋白法检测粪便隐血，对大肠肿瘤具有高度的敏感性和特异性。Hirata等 [<xref ref-type="bibr" rid="hanspub.26582-ref11">11</xref>] 对转铁蛋白及血红蛋白进行定量检测，结果显示转铁蛋白法和免疫法对大肠癌的敏感性均为50%，二者联合检测时对大肠癌的敏感性为61.1%，联合检测可以提高诊断大肠疾病的敏感性和效率。Sheng等 [<xref ref-type="bibr" rid="hanspub.26582-ref12">12</xref>] 研究发现，转铁蛋白法检测大肠癌和癌前病变的阳性率明显高于免疫法。Chen等 [<xref ref-type="bibr" rid="hanspub.26582-ref13">13</xref>] 采取化学法、免疫法和转铁蛋白法对大肠癌高危人群进行筛查，发现转铁蛋白法和免疫法对大肠癌敏感性分别是62%，特异性是74.5%；对癌前病变的敏感性是69%，特异性是75.5%；联合这三种方法可以明显提高大肠癌和癌前病变的敏感性，分别是69%和88%。认为转铁蛋白法可以应用于高危人群的大肠癌和癌前病变筛查，三种方法联合检测可以显著提高诊断大肠癌和癌前病变的敏感性。</p><p>粪便隐血试验作为大肠癌的筛查工具，虽有一定效果，但对发现大肠肿瘤意义有限，需结合其他方法。</p></sec></sec><sec id="s5"><title>3. 粪便大肠脱落细胞检测(Detection of Fecal Colonic Exfoliative Cells)</title><p>大肠本身及肿瘤都会产生大量的脱落细胞，肿瘤细胞比正常细胞更新快粘附力差，更易脱落 [<xref ref-type="bibr" rid="hanspub.26582-ref14">14</xref>] 。该法包括两类检测：粪便脱落细胞学检测和粪便脱落细胞成分检测。</p><sec id="s5_1"><title>3.1. 粪便脱落细胞学检测</title><sec id="s5_1_1"><title>3.1.1. 大肠脱落细胞肿瘤标记物</title><p>从粪便中回收的脱落细胞数目较少，加之粪便对细胞的破坏，人们很难用形态学标准来区分良恶性细胞。粪便中脱落肿瘤细胞的分子标记物引起人们的重视，如微小染色体维持蛋白(MCM)家族，它们是真核细胞在细胞周期中启动DNA复制的关键蛋白 [<xref ref-type="bibr" rid="hanspub.26582-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.26582-ref16">16</xref>] ，只存在于处于细胞周期中的细胞(如结直肠肿瘤细胞)，故其可作为上皮细胞进展为肿瘤细胞的标志。Davies等 [<xref ref-type="bibr" rid="hanspub.26582-ref17">17</xref>] 研究显示，40例大肠癌患者中37例有MCM阳性，而正常对照者粪便中均未检测到MCM阳性。</p></sec><sec id="s5_1_2"><title>3.1.2. 大肠脱落细胞DNA倍体分析</title><p>染色体或倍体不稳定性(chromosome nstability, CIN)是结直肠癌变过程中最常见的基因组不稳定性。Yiu等 [<xref ref-type="bibr" rid="hanspub.26582-ref18">18</xref>] 研究发现，85%的大肠癌患者中会出现CIN。Gerrits等 [<xref ref-type="bibr" rid="hanspub.26582-ref19">19</xref>] 研究显示，DNA倍体异常是大肠炎症性疾病患者癌变的重要危险因素，可用于大肠癌的早期筛查。Dewhurst等 [<xref ref-type="bibr" rid="hanspub.26582-ref20">20</xref>] 发现染色体分离错误和四倍体耐受可导致CIN的发生，进而促进癌变的进展。</p></sec></sec><sec id="s5_2"><title>3.2. 粪便脱落细胞成分检测</title><p>粪便由于富含胆汁酸、细胞毒性物质等复杂成分，人们很难直接从粪便标本中获得完整的大肠脱落细胞，故人们尝试利用脱落细胞裂解后的成分进行大肠肿瘤的早期筛查。目前基于粪便脱落细胞成分的DNA、RNA及蛋白质标记物的检测是大肠癌筛查的研究重点。</p><sec id="s5_2_1"><title>3.2.1. 粪便脱落细胞DNA检测</title><p>Sidransky于1992年对大肠癌患者粪便脱落细胞K-RAS基因的突变进行检测，用于大肠癌的筛查。随后，其他与大肠癌变相关的基因如APC、CTNNB1、BRAF等相继被用于大肠癌的筛查。这些相关基因主要通过干扰信号通路的功能或影响DNA修复或增殖基因的功能引起结直肠上皮细胞的癌变 [<xref ref-type="bibr" rid="hanspub.26582-ref21">21</xref>] 。Thompson等 [<xref ref-type="bibr" rid="hanspub.26582-ref22">22</xref>] 研究显示，TP53基因突变可导致机体对染色体不稳的耐受性，进而加速细胞的癌变，对恶性肿瘤的发生具有重要的提示作用。Kanthan等 [<xref ref-type="bibr" rid="hanspub.26582-ref23">23</xref>] 研究发现，突变的APC蛋白不能下调和抑制WNT信号通路中的β-连环蛋白，进而转录因子TCF4和下游的癌基因(如MYC)被不恰当地激活，导致结直肠肿瘤的发生。</p><p>粪便脱落细胞表观遗传学分子标记物可用于结直肠肿瘤的筛查试验中，主要有MSI、L-DNA和甲基化三类。Davies等 [<xref ref-type="bibr" rid="hanspub.26582-ref24">24</xref>] 研究显示，MSI对近端结直肠癌诊断的敏感性可达40%。Levin等 [<xref ref-type="bibr" rid="hanspub.26582-ref25">25</xref>] 研究显示，L-DNA对结直肠癌诊断的敏感性为79%，特异性为89%。Zou等 [<xref ref-type="bibr" rid="hanspub.26582-ref26">26</xref>] 对4个甲基化基因(BMP3、NDRG4、VIM、TFPI2)进行检测，结果显示这4个甲基化基因联合对大肠癌及腺瘤诊断的特异性均为100%，对大肠癌诊断的敏感性为100%，对腺瘤诊断的敏感性为6%。</p><p>由于单基因实验很难达到人们期望的诊断敏感性与特异性，所以人们尝试了不同的基因与表观遗传学生物标记物组合用于结直肠癌及癌前病变的筛查。其中，MT-sDNA组合有极好的诊断敏感性及特异性。Lidgard等 [<xref ref-type="bibr" rid="hanspub.26582-ref27">27</xref>] 研究显示，2个甲基化基因(NDRG4、BMP3)、K-RAS突变基因和大便潜血试验组合对大肠癌诊断的敏感性为98%、对&gt;1 cm的进展期腺瘤和息肉诊断的敏感性为57%，对腺瘤合并高级别非典型增生诊断的敏感性为83%，特异性为90%。Imperiale等 [<xref ref-type="bibr" rid="hanspub.26582-ref28">28</xref>] 研究显示，MT-sDNA对大肠癌诊断的敏感性为92%，对进展期腺瘤诊断的敏感性为42%，对&gt;1 cm的息肉诊断的敏感性为42%，特异性为87%。</p></sec><sec id="s5_2_2"><title>3.2.2. 粪便脱落细胞RNA检测</title><p>由于RNA在粪便的环境中较DNA更容易降解，粪便中RNA的检测的应用没有DNA那样广泛。近年来，由于RNA-later保存液的使用，RNA的检测也得到重视。对于RNA标记物的研究从单链的mRNA展开，其总体的灵敏度在41%~90%之间，特异度在87%~100%之间 [<xref ref-type="bibr" rid="hanspub.26582-ref29">29</xref>] 。Takai T等 [<xref ref-type="bibr" rid="hanspub.26582-ref30">30</xref>] 检测４种不同的RNA标记物，测得它们对大肠癌诊断的灵敏度为58%，特异度为88%。Lagerholm等 [<xref ref-type="bibr" rid="hanspub.26582-ref31">31</xref>] 提取粪便脱落细胞RNA后，通过RT-PCR分析c-myc的相对表达量。结果显示，78.6%的大肠癌患者粪便RNA中c-myc的表达为阳性，而正常人的粪便RNA中只有13.3%为阳性，并且大肠癌患者和正常人的c-myc相对表达量有显著差异(P &lt; 0.05)。提示c-myc可作为大肠癌早期诊断的标记。</p></sec><sec id="s5_2_3"><title>3.2.3. 粪便脱落细胞蛋白标记物</title><p>粪便脱落细胞蛋白标记物较DAN及RNA更容易获得。蛋白质容易在粪便中降解，产生阴性的结果，因此对于粪便中蛋白标记物的提取及保存尤为重要。</p><p>Ahmed等 [<xref ref-type="bibr" rid="hanspub.26582-ref32">32</xref>] 运用免疫化学冷光法检测粪便中结合珠蛋白–血红蛋白复合物，当阳性阔值在2.0 ug/g粪便时，对大肠癌诊断的敏感度为83%，特异度为96%。Davies等 [<xref ref-type="bibr" rid="hanspub.26582-ref17">17</xref>] 联合检测粪便中结合珠蛋白-血红蛋白复合物和S100钙结合蛋白A12 (100A12)，显示其对大肠癌诊断的灵敏度为88%，特异度为95%；再联合金属肽酶抑制剂-1 (TIMP1)检测，显示三项联合检测对大肠癌诊断的特异度为98%，灵敏度为82%。以上两项或三项的联合检测对于大肠癌的检出率明显高于单一的iFOBT。Qimye等 [<xref ref-type="bibr" rid="hanspub.26582-ref33">33</xref>] 研究显示，微型染色体保持复合物(MCM2)对大肠癌诊断的灵敏度为93%，特异度为100%。然而MCM2需用免疫组化的方法进行测定，用于大肠癌的大规模筛查有一定困难。</p><p>综上所述，粪便隐血试验作为目前应用最广泛的筛查手段，已初具成效，但需结合其他方法；粪便脱落细胞在癌前病变的监测和大肠癌的早期诊断上有着广阔的应用前景，但其大规模筛查的效果仍有待验证。</p></sec></sec></sec><sec id="s6"><title>基金项目</title><p>湖北科技学院临床医学重点(培育)学科专项课题(编号：LCZX201517)。</p></sec><sec id="s7"><title>文章引用</title><p>卢葵花. 以粪便为基础的大肠癌筛查 The Screening for Colorectal Cancer on the Basis of Feces[J]. 临床医学进展, 2018, 08(06): 590-595. https://doi.org/10.12677/ACM.2018.86099</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26582-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李鹏, 王拥军, 陈光勇, 等. 中国早期结直肠癌及癌前病变筛查与诊治共识[J]. 中国实用内科杂志, 2015, 35(3): 211-227.</mixed-citation></ref><ref id="hanspub.26582-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Li, R., Liu, J., Xue, H., et al. (2012) Diagnostic Value of Fecal Tumor M2-Pyruvate Kinase for CRC Screening: A Systematic Review and Meta-Analysis. International Journal of Cancer, 131, 1837-1845.  
&lt;br&gt;https://doi.org/10.1002/ijc.27442</mixed-citation></ref><ref id="hanspub.26582-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Potack, J. and Itzkowitz, S.H. (2010) Practical Advances in Stool Screening for Colorectal Cancer. Journal of the National Comprehensive Cancer Network, 8, 81-92. &lt;br&gt;https://doi.org/10.6004/jnccn.2010.0005</mixed-citation></ref><ref id="hanspub.26582-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lindholm, E., Brevinge, H. and Haglind, E. (2008) Survival Benefit in a Randomized Clinical Trial of Faecal Occult Blood Screening for Colorectal Cancer. The British Journal of Surgery, 95, 1029-1036.  
&lt;br&gt;https://doi.org/10.1002/bjs.6136</mixed-citation></ref><ref id="hanspub.26582-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, M.M., Xu, X.T., Nie, F., et al. (2010) Comparison of Immunochemical and Guaiacbased Fecal Occult Blood Test in Screening and Surveillance for Advanced Colorectal Neoplasms: A Meta-Analysis. Journal of Digestive Diseases, 11, 148-160. &lt;br&gt;https://doi.org/10.1111/j.1751-2980.2010.00430.x</mixed-citation></ref><ref id="hanspub.26582-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lane, J.M., Chou, W., Young, G.P., et al. (2010) Interval Fecal Immunochemical Testing in a Colonoscopic Surveillance Program Speeds Detection of Colorectal Neoplasia. Gastroenterology, 139, 1918-1926.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2010.08.005</mixed-citation></ref><ref id="hanspub.26582-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Faivre, J., Dancourt, V. and Lejeune, C. (2012) Screening for Colorectal Cancer with Immunochemical Faecal Occult Blood Tests. Digestive and Liver Disease, 44, 967-973. &lt;br&gt;https://doi.org/10.1016/j.dld.2012.07.004</mixed-citation></ref><ref id="hanspub.26582-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Morikawa, T., Kato, J., Yamaji, Y., et al. (2005) A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonos Copy in the a Symptomatic Population. Gastroenter-ology, 129, 422-428.  
&lt;br&gt;https://doi.org/10.1016/j.gastro.2005.05.056</mixed-citation></ref><ref id="hanspub.26582-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Allison, J.E., Sakoda, L.C., Levin, T.R., et al. (2007) Screening for Colorectal Neoplasms with New Fecal Occult Blood Tests: Update on Perform an Cecharacteristics. Journal of the National Cancer Institute, 99, 1462-1470.</mixed-citation></ref><ref id="hanspub.26582-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Miyoshi, H., Oka, M., Sugi, K., et al. (2000) Accuracy of Detection of Colorectal Neoplasia Using an Immunochemical Occult Blood Test in Symptomatic Referred Patients: Comparison of Retrospective and Prospective Studies. Internal Medicine, 39, 701-706. &lt;br&gt;https://doi.org/10.2169/internalmedicine.39.701</mixed-citation></ref><ref id="hanspub.26582-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hirata, I., Hoshimoto, M., Saito, O., et al. (2007) Usefulness of Fecal Lactoferrin and Hemoglobin in Diagnosis of Colorectal Diseases. World Journal of Gastroenterology, 13, 1569-1574. &lt;br&gt;https://doi.org/10.3748/wjg.v13.i10.1569</mixed-citation></ref><ref id="hanspub.26582-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sheng, J.Q., Li, S.R., Wu, Z.T., et al. (2009) Transferrin Dipstick as a Potential Novel Test for Colon Cancer Screening : A Comparative Study With Immuno Fecal Occult Blood Test. Cancer Epidemiology, Biomarkers &amp; Prevention, 18, 2182-2185. &lt;br&gt;https://doi.org/10.1158/1055-9965.EPI-09-0309</mixed-citation></ref><ref id="hanspub.26582-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J.G., Cai, J., Wu, H.L., et al. (2012) Colorectal Cancer Screening: Comparison of Transferrin and Immuno Fecal Occult Blood Test. World Journal of Gastroenterology, 18, 2682-2688. &lt;br&gt;https://doi.org/10.3748/wjg.v18.i21.2682</mixed-citation></ref><ref id="hanspub.26582-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Osborn, N.K. and hlquist, D.A. (2005) Stool Screening for Colorectal Cancer: Molecular Approaches. Gastroenterology, 128, 192-206. &lt;br&gt;https://doi.org/10.1053/j.gastro.2004.10.041</mixed-citation></ref><ref id="hanspub.26582-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., He, G., Wang, Y., et al. (2013) MCM-2 Is a Therapeutic Target of Trichostatin A in Colon Cancer Cells. Toxicology Letters, 221, 23-30. &lt;br&gt;https://doi.org/10.1016/j.toxlet.2013.05.643</mixed-citation></ref><ref id="hanspub.26582-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wei, Q., Li, J., Liu, T., et al. (2013) Phosphorylation of Mini-chromosome Maintenance Protein 7 (MCM7) by Cyclin/Cyclin-Dependent Kinase Affects Its Function in Cell Cycle Regulation. Journal of Biological Chemistry, 288, 19715-19725. &lt;br&gt;https://doi.org/10.1074/jbc.M112.449652</mixed-citation></ref><ref id="hanspub.26582-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Davies, R.J., Freeman, A., Morris, L.S., et al. (2002) Analysis of Minichromosome Maintenance Proteins as a Novel Method for Detection of Colorectal Cancer in Stool. The Lancet, 359, 1917-1919.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(02)08739-1</mixed-citation></ref><ref id="hanspub.26582-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yiu, A.J. and Yiu, C.Y. (2016) Biomarkers in Colorectal Cancer. Anticancer Research, 36, 1093-1102.</mixed-citation></ref><ref id="hanspub.26582-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gerrits, M.M., Chen, M., Theeuwes, M., et al. (2011) Bi-omarker-Based Prediction of Inflammatory Bowel Disease-Related Colorectal Cancer: A Case Control Study. Cellular Oncology, 34, 107-117.  
&lt;br&gt;https://doi.org/10.1007/s13402-010-0006-4</mixed-citation></ref><ref id="hanspub.26582-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dewhurst, S.M., Mcgranahan, N., Burrell, R.A., et al. (2014) Tolerance of Whole Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. Cancer Discovery, 4, 175-185.  
&lt;br&gt;https://doi.org/10.1158/2159-8290.CD-13-0285</mixed-citation></ref><ref id="hanspub.26582-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Brennan, C.W., Verhaak, R.G., Mckenna, A., et al. (2013) The Somatic Genomic Landscape of Glioblastoma. Cell, 155, 462-477. &lt;br&gt;https://doi.org/10.1016/j.cell.2013.09.034</mixed-citation></ref><ref id="hanspub.26582-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Thompson, S.L. and Compton, D.A. (2010) Proliferation of An-euploid Human Cells Is Limited by a p53-Dependent Mechanism. The Journal of Cell Biology, 188, 369-381. &lt;br&gt;https://doi.org/10.1083/jcb.200905057</mixed-citation></ref><ref id="hanspub.26582-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kanthan, R., Senger, J.L. and Kanthan, S.C. (2012) Fecal Molecular Markers for Colorectal Cancer Screening. Gastroenterology Research and Practice, 2012, Article ID: 184343.</mixed-citation></ref><ref id="hanspub.26582-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Davies, R.J., Miller, R. and Coleman, N. (2005) Colorectal Cancer Screening: Prospects for Molecular Stool Analysis. Nature Reviews Cancer, 5, 199-209. &lt;br&gt;https://doi.org/10.1038/nrc1569</mixed-citation></ref><ref id="hanspub.26582-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Levin, B. (2006) Mo-lecular Screening Testing for Colorectal Cancer. Clinical Cancer Research, 12, 5014-5017.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-06-0578</mixed-citation></ref><ref id="hanspub.26582-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Zou, H., Allawi, H., Cao, X., et al. (2012) Quantification of Methylated Markers with a Multiplex Methylation-Specific Technology. Clinical Chemistry, 58, 375-383. &lt;br&gt;https://doi.org/10.1373/clinchem.2011.171264</mixed-citation></ref><ref id="hanspub.26582-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lidgard, G.P., Domanico, M.J., Bruinsma, J.J., et al. (2013) Clinical Performance of an Automated Stool DNA Assay for Detection of Colorectal Neoplasia. Clinical Gastroenter-ology and Hepatology, 11, 1313-1318.  
&lt;br&gt;https://doi.org/10.1016/j.cgh.2013.04.023</mixed-citation></ref><ref id="hanspub.26582-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., et al. (2014) Multitarget Stool DNA Testing for Colorectal-Cancer Screening. The New England Journal of Medicine, 370, 1287-1297. &lt;br&gt;https://doi.org/10.1056/NEJMoa1311194</mixed-citation></ref><ref id="hanspub.26582-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Bosch, L.J.W., Carvalho, B., Fijneman, R.J.A., Jimenez, C.R., et al. (2011) Molecular Tests for Colorectal Cancer Screening. Clinical Colorectal Cancer, 10, 8-23. &lt;br&gt;https://doi.org/10.3816/CCC.2011.n.002</mixed-citation></ref><ref id="hanspub.26582-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Takai, T., Kanaoka, S., Yoshida, K., et al. (2009) Fecal Cyclooxy-genase2 plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal? Cancer Screening. Cancer Epide-miology, Biomarkers &amp; Prevention, 18, 1888-1893.</mixed-citation></ref><ref id="hanspub.26582-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Lagerholm, S., Dutta, S. and Nair, P. (2005) Non-Invasive Detection of c-myc p64, c-myc p67 and c-erbb-2 in Colorectal Cancer. Scandinavian Journal of Gastroenterology, 40, 1343-1350. &lt;br&gt;https://doi.org/10.1080/00365520510023549</mixed-citation></ref><ref id="hanspub.26582-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, F.E., Jeffries, C.D., Vos, P.W., et al. (2009) Diagnostic microRNA Markers for Screening Sporadic Human Colon Cancer and Active Ulcerative Colitis in Stool and Tissue. Cancer Genomics Proteomics, 6, 281-295.</mixed-citation></ref><ref id="hanspub.26582-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Qimye, I.K. (2008) Haptoglobin, Inflammation and Disease. Transactions of the Royal Society of Tropical Medicine and Hygiene, 102, 735-742. &lt;br&gt;https://doi.org/10.1016/j.trstmh.2008.04.010</mixed-citation></ref></ref-list></back></article>